Dynavax Technologies Corporation (NASDAQ:DVAX)‘s stock had its “buy” rating reissued by Cowen and Company in a report issued on Friday. They presently have a $30.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 38.89% from the stock’s previous close.

The analysts wrote, “Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in.””

Several other brokerages have also issued reports on DVAX. Cantor Fitzgerald assumed coverage on Dynavax Technologies Corporation in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 target price (up from $26.00) on shares of Dynavax Technologies Corporation in a research note on Monday, September 25th. ValuEngine upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. William Blair restated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $25.00.

Shares of Dynavax Technologies Corporation (DVAX) traded up $0.60 during trading on Friday, reaching $21.60. The company had a trading volume of 1,396,470 shares, compared to its average volume of 1,408,759.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. Dynavax Technologies Corporation’s quarterly revenue was down 68.8% compared to the same quarter last year. During the same period last year, the company posted ($0.90) earnings per share. equities analysts expect that Dynavax Technologies Corporation will post -1.74 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Corporation (DVAX) Earns “Buy” Rating from Cowen and Company” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/04/dynavax-technologies-corporation-dvax-earns-buy-rating-from-cowen-and-company.html.

Large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its stake in shares of Dynavax Technologies Corporation by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Dynavax Technologies Corporation by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,700 shares during the period. Bank of America Corp DE raised its stake in shares of Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 456 shares during the period. Legal & General Group Plc raised its stake in shares of Dynavax Technologies Corporation by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 1,950 shares during the period. Finally, Wall Street Access Asset Management LLC bought a new stake in shares of Dynavax Technologies Corporation during the 2nd quarter valued at $124,000. Institutional investors own 59.90% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.